Osteoporotic Fractures, Osteoporosis, Postmenopausal
Conditions
Keywords
bone mineral density, 25(OH)D
Brief summary
This proposed study was designed to investigate the prevalence of a 5-year incident osteoporotic fracture and evaluate the association of a 5-year change of 25-hydroxyvitamin D (25\[OH\]D)/bone turnover makers/bone mineral density (BMD) with the incident fracture in the Chinese postmenopausal women, based on an endeavor of a 5-year post-baseline follow-up visit of a previous cross-sectional study, PK-VF, in which 1724 participants were enrolled and examined.
Detailed description
1. In 2013, 5 years after PK-VF, the same 2070 subjects were contacted by the original sites. Among them 1242 subjects were able to come for the follow-up assessment. 2. Clinical assessments: The participant's bio-information, physical examination and medical history were collected;Questionnaire including social/life style and medical evaluations (years since menopause (YSM), fracture history, milk/yoghourt/coffee/wine intake, calcium intake, or smoking history) were collected by PK-VF investigators. Non-vertebral fracture history evaluation: specific non-vertebral fracture sites include rib or clavicle, forearm, upper arm, hand (including wrist), pelvis, hip, thigh (not including hip), leg, and foot (including ankle). When non-vertebral fractures are suspected, questions were raised to the participant to eliminate possible biases (How did you get these fractures, a slight fall at home, fell from a high place, hit by someone, broken during a car accident or an operation? Did you see a doctor to confirm these fractures?) A fracture occurred in regular daily activities or due to mild trauma was defined as fragile non-vertebral fracture. 3. Biochemical measurements: Fasting blood sample (\ 5 ml) was collected from each participant at participating sites; In 2007-2008 study, blood samples were collected during April-July, while in the 5-year follow-up; samples were collected in the same period of time. C-terminal telopeptide of type I collagen (β-CTX), N-aminoterminal prepeptide of type I procollagen (P1NP), and 25 (OH) D will be determined by a laboratory method of electrochemiluminescence (E170; Roche Diagnostics, Basel, Switzerland) in the institute (Peking Union); Chemistry including alkaline phosphatase (ALP), calcium (Ca), creatinine (Cr), and glucose, will be measured by using automated techniques in the institute (Peking Union); 4. BMD measurements: Lumbar spine (LS) and femoral neck (FN) BMDs by dual-energy x-ray absorptiometry (DXA) (Lunar or Norland) at PK-VF sites. BMD calibration: The participant's BMD were evaluated by the same type of DXA as previous. The coefficients of variation of the seven hospitals were 0.75% to 1.7% for LS and 0.56% to 1.0% for FN. Cross-calibration equations between machines are: LS BMD (g/cm\^2) Lunar = 1.012 × Norland + 0.0137 and, FN BMD (g/cm\^2) Lunar = 1.0377 × Norland + 0.00026 5. Vertebral fracture diagnosis: Lateral radiographs of the thoracolumbar spine (T4-L5) were taken at PK-VF sites. Vertebral fractures will be assessed using Genant's semi-quantitative visual criteria. Two specialist radiologists will independently evaluate and diagnose vertebral fracture. A worsened existing vertebral fracture will be regarded as a new vertebral fracture. In 2007-2008 study(Published article about this study could be found in Pubmed, PMID: 24760246), 2070 participants were recruited in this cohort, and 837 subjects (40%) were diagnosed as osteoporosis. After 5 years, 1242 subjects agreed to be re-evaluated in 2013. Questionnaires and blood samples were collected, and BMD and spine x-ray were obtained at the 5-year follow up. We estimate that around 625 subjects would be diagnosed as osteoporosis. The remaining works include blood sample test (25(OH)D, CTX and P1NP),spine x-ray films reading, data input and statistical analysis, paper writing and publication.
Interventions
We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
Sponsors
Study design
Eligibility
Inclusion criteria
1. postmenopausal women (normally over 50 years old and years since menopause over than 1 year) in Peking. 2. participants without any fracture in 2007 PK-VF study were included in the prospective study investigating the association of bone turnover markers/BMD/25(OH)D with fracture incidence.
Exclusion criteria
participants with years since menopause less than 1 year.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Non-vertebral Fracture Incidence | 5 year | Non-vertebral fractures were assessed by questionnaire survey.The overall incidence of non-vertebral fracture of the subjects is 7.18%( 70/975). |
| Vertebral Fracture Incidence | 5 year | Vertebral fractures were assessed by lateral radiograph. The overall incidence of vertebral fracture of the subjects is 5.23%( 51/975) |
| Bone Mineral Density | 5 year | bone mineral density of Lumbar spine and femoral neck were measured by dual-energy X-ray absorptiometry (DXA) (Lunar or Norland) |
| Bone Turnover Markers and 25(OH)D | 5 year | C-terminal telopeptide of type I collagen (β-CTX), N-aminoterminal prepeptide of type I procollagen (P1NP), and 25-hydroxyvitamin D (25\[OH\]D) will be determined by a laboratory method of electrochemiluminescence (E170; Roche Diagnostics, Basel, Switzerland) in the institute (Peking Union) |
| Biochemical Markers | 5 year | Fasting blood sample was collected for each subject. Common biochemical markers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP)were analyzed. |
| Serum Alkaline Phosphatase | 5 years | Fasting blood sample was collected for each subject. The level of serum alkaline phosphatase (ALP) was analyzed. |
| Serum Creatinine | 5 years | Fasting blood sample was collected for each subject.The level of serum creatinine(Cr) was analyzed. |
Countries
China
Participant flow
Recruitment details
In 2007-2008, 2070 postmenopausal women participated in the previous PK-VF study. After 5 years, 1100 subjects agreed to be re-evaluated in 2013.
Pre-assignment details
All participants who agreed to be re-evaluated were enrolled in this study.
Participants by arm
| Arm | Count |
|---|---|
| Fracture Group Fracture group included participants with new fractures during the 5 year follow-up visit. Fracture consists of non-vertebral fracture and vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively. | 111 |
| Non-fracture Group Non-fracture group included participants without new fractures during the 5 year follow-up visit. Fracture consists of vertebral fracture and non-vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively. | 864 |
| Total | 975 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Poor quality of radiological results | 125 |
Baseline characteristics
| Characteristic | Fracture Group | Non-fracture Group | Total |
|---|---|---|---|
| Age, Continuous | 70.08 years | 66.09 years | 66.72 years |
| Body mass index | 25.21 kg/m^2 STANDARD_DEVIATION 5.04 | 25.47 kg/m^2 STANDARD_DEVIATION 4.85 | 25.46 kg/m^2 STANDARD_DEVIATION 4.82 |
| Previous osteoporotic fracture No previous osteoporotic fracture | 39 participants | 576 participants | 615 participants |
| Previous osteoporotic fracture Previous osteoporotic fracture | 72 participants | 288 participants | 360 participants |
| Sex: Female, Male Female | 111 Participants | 864 Participants | 975 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
| Years since menopause | 21.36 years | 16.43 years | 16.92 years |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 975 |
| serious Total, serious adverse events | 0 / 975 |
Outcome results
Biochemical Markers
Fasting blood sample was collected for each subject. Common biochemical markers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP)were analyzed.
Time frame: 5 year
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Fracture Group | Biochemical Markers | Serum calcium | 2.302 mmol/L | Standard Deviation 0.565 |
| Fracture Group | Biochemical Markers | Serum phosphate | 1.148 mmol/L | Standard Deviation 0.22 |
| Fracture Group | Biochemical Markers | Serum glucose | 6.083 mmol/L | Standard Deviation 1.81 |
| Non-fracture Group | Biochemical Markers | Serum calcium | 2.263 mmol/L | Standard Deviation 0.625 |
| Non-fracture Group | Biochemical Markers | Serum phosphate | 1.122 mmol/L | Standard Deviation 0.345 |
| Non-fracture Group | Biochemical Markers | Serum glucose | 6.112 mmol/L | Standard Deviation 1.281 |
Bone Mineral Density
bone mineral density of Lumbar spine and femoral neck were measured by dual-energy X-ray absorptiometry (DXA) (Lunar or Norland)
Time frame: 5 year
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Fracture Group | Bone Mineral Density | Lumbar spine BMD | 0.907 g/cm^2 |
| Fracture Group | Bone Mineral Density | Femoral neck BMD | 0.686 g/cm^2 |
| Fracture Group | Bone Mineral Density | Total hip BMD | 0.788 g/cm^2 |
| Non-fracture Group | Bone Mineral Density | Lumbar spine BMD | 0.956 g/cm^2 |
| Non-fracture Group | Bone Mineral Density | Femoral neck BMD | 0.732 g/cm^2 |
| Non-fracture Group | Bone Mineral Density | Total hip BMD | 0.845 g/cm^2 |
Bone Turnover Markers and 25(OH)D
C-terminal telopeptide of type I collagen (β-CTX), N-aminoterminal prepeptide of type I procollagen (P1NP), and 25-hydroxyvitamin D (25\[OH\]D) will be determined by a laboratory method of electrochemiluminescence (E170; Roche Diagnostics, Basel, Switzerland) in the institute (Peking Union)
Time frame: 5 year
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Fracture Group | Bone Turnover Markers and 25(OH)D | 25(OH)D | 13.21 ng/ml |
| Fracture Group | Bone Turnover Markers and 25(OH)D | β-CTX | 0.437 ng/ml |
| Fracture Group | Bone Turnover Markers and 25(OH)D | P1NP | 51.88 ng/ml |
| Non-fracture Group | Bone Turnover Markers and 25(OH)D | β-CTX | 0.401 ng/ml |
| Non-fracture Group | Bone Turnover Markers and 25(OH)D | P1NP | 51.57 ng/ml |
| Non-fracture Group | Bone Turnover Markers and 25(OH)D | 25(OH)D | 12.49 ng/ml |
Non-vertebral Fracture Incidence
Non-vertebral fractures were assessed by questionnaire survey.The overall incidence of non-vertebral fracture of the subjects is 7.18%( 70/975).
Time frame: 5 year
Population: In 1100 participants, 975 of them finished the questionnaire
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fracture Group | Non-vertebral Fracture Incidence | 70 participants |
| Non-fracture Group | Non-vertebral Fracture Incidence | 0 participants |
Serum Alkaline Phosphatase
Fasting blood sample was collected for each subject. The level of serum alkaline phosphatase (ALP) was analyzed.
Time frame: 5 years
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Fracture Group | Serum Alkaline Phosphatase | 79.4 U/L | Standard Deviation 33 |
| Non-fracture Group | Serum Alkaline Phosphatase | 77.5 U/L | Standard Deviation 37 |
Serum Creatinine
Fasting blood sample was collected for each subject.The level of serum creatinine(Cr) was analyzed.
Time frame: 5 years
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Fracture Group | Serum Creatinine | 62.77 umol/l | Standard Error 17.73 |
| Non-fracture Group | Serum Creatinine | 64.91 umol/l | Standard Error 14.59 |
Vertebral Fracture Incidence
Vertebral fractures were assessed by lateral radiograph. The overall incidence of vertebral fracture of the subjects is 5.23%( 51/975)
Time frame: 5 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fracture Group | Vertebral Fracture Incidence | 51 participants |
| Non-fracture Group | Vertebral Fracture Incidence | 0 participants |